Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions
Presbyopia
Interventions
DRUG

0.1% STN1013600 ophthalmic solution

0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months

DRUG

0.3% STN1013600 ophthalmic solution

0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months

DRUG

Placebo

Placebo ophthalmic solution 1 drop BID for 2 months

Trial Locations (12)

14618

Rochester Ophthalmological Group, P.C., Rochester

16066

Scott Christie and Associates PC, Cranberry Township

28803

Asheville Eye Associates, Asheville

30260

Clayton Eye Clinical Research, LLC, Morrow

37803

University Eye Specialists, Maryville

38119

Total Eye Care PA, Memphis

57108

Vance Thompson Vision Clinic, Sioux Falls

63090

Comprehensive Eye Care, Ltd, Washington

78229

R and R Eye Research LLC, San Antonio

79902

The Cataract and Glaucoma Center, El Paso

91204

Global Research Management Inc, Glendale

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors
lead

Santen Inc.

INDUSTRY